Sirtuin 6 protects against hepatic fibrogenesis by suppressing the YAP and TAZ function
Authors:
Open Access
- 29 August 2022
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 36 (10) , e22529
Abstract
Hepatic fibrosis occurs in response to prolonged tissue injury in the liver, which results in abnormal accumulation of extracellular matrix. Hepatic stellate cells (HSCs) have been suggested to play a major role in liver fibrosis. However, the molecular mechanisms remain incompletely understood. Sirtuin 6 (SIRT6), an NAD + ‐dependent deacetylase, has been previously implicated in the regulation of the transforming growth factor β (TGFβ)‐SMAD3 pathway that plays a significant role in liver fibrosis. In this work, we aimed to identify other important players during hepatic fibrogenesis, which are modulated by SIRT6. Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ or WWTR1), key players in the Hippo pathway, have been implicated in the promotion of hepatic fibrosis. Our data show that HSC‐specific Sirt6 knockout mice are more susceptible to high‐fat‐cholesterol‐cholate diet‐induced hepatic fibrosis than their wildtype counterparts. Our signaling analyses suggest that in addition to the TGFβ‐SMAD3 pathway, YAP and TAZ are also highly activated in the SIRT6‐deficient HSCs. As it is not clear how SIRT6 might regulate YAP and TAZ, we have decided to elucidate the mechanism underlying the regulation of YAP and TAZ by SIRT6 in HSCs. Overexpression or knockdown of SIRT6 corroborates the role of SIRT6 in the negative regulation of YAP and TAZ. Further biochemical analyses reveal that SIRT6 deacetylates YAP and TAZ and reprograms the composition of the TEA domain transcription factor complex to suppress their downstream target genes, particularly those involved in hepatic fibrosis. In conclusion, our data suggest that SIRT6 plays a critical role in the regulation of the Hippo pathway to protect against hepatic fibrosis.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK121925, R01DK120689)
- National Institute on Aging (R21AG072288)
- National Institute on Alcohol Abuse and Alcoholism (R01AA028506)
This publication has 34 references indexed in Scilit:
- Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic SteatohepatitisCell Metabolism, 2016
- PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosisNature Communications, 2016
- ω-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP/TAZ degradationScientific Reports, 2016
- Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease SpectrumAnnual Review of Pathology: Mechanisms of Disease, 2016
- The Hippo pathway effector YAP controls mouse hepatic stellate cell activationJournal of Hepatology, 2015
- High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse liversNature Protocols, 2015
- Isolation and culture of hepatic stellate cells from mouse liverActa Biochimica et Biophysica Sinica, 2014
- Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiologyNature Communications, 2013
- SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinomaOncogene, 2013
- A Novel Acetylation Cycle of Transcription Co-activator Yes-associated Protein That Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating AgentsJournal of Biological Chemistry, 2012